Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Schaller, S; Lippert, J; Schaupp, L; Pieber, TR; Schuppert, A; Eissing, T.
Robust PBPK/PD-Based Model Predictive Control of Blood Glucose.
IEEE Trans Biomed Eng. 2016; 63(7):1492-1504
Doi: 10.1109/TBME.2015.2497273
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Pieber Thomas
- Schaupp Lukas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Automated glucose control (AGC) has not yet reached the point where it can be applied clinically [3]. Challenges are accuracy of subcutaneous (SC) glucose sensors, physiological lag times, and both inter- and intraindividual variability. To address above issues, we developed a novel scheme for MPC that can be applied to AGC. An individualizable generic whole-body physiology-based pharmacokinetic and dynamics (PBPK/PD) model of the glucose, insulin, and glucagon metabolism has been used as the predictive kernel. The high level of mechanistic detail represented by the model takes full advantage of the potential of MPC and may make long-term prediction possible as it captures at least some relevant sources of variability [4]. Robustness against uncertainties was increased by a control cascade relying on proportional-integrative derivative-based offset control. The performance of this AGC scheme was evaluated in silico and retrospectively using data from clinical trials. This analysis revealed that our approach handles sensor noise with a MARD of 10%-14%, and model uncertainties and disturbances. The results suggest that PBPK/PD models are well suited for MPC in a glucose control setting, and that their predictive power in combination with the integrated database-driven (a priori individualizable) model framework will help overcome current challenges in the development of AGC systems. This study provides a new, generic, and robust mechanistic approach to AGC using a PBPK platform with extensive a priori (database) knowledge for individualization.
- Find related publications in this database (using NLM MeSH Indexing)
- Algorithms -
- Blood Glucose - analysis
- Blood Glucose - drug effects
- Computer Simulation -
- Decision Making, Computer-Assisted -
- Diabetes Mellitus, Type 1 - metabolism
- Glucagon - analysis
- Glucagon - metabolism
- Humans -
- Hypoglycemic Agents - administration & dosage
- Hypoglycemic Agents - pharmacokinetics
- Hypoglycemic Agents - pharmacology
- Insulin - analysis
- Insulin - metabolism
- Insulin - pharmacology
- Models, Biological -
- Models, Statistical -
- Monitoring, Physiologic -
- Pancreas, Artificial -
- Subcutaneous Tissue - chemistry
- Find related publications in this database (Keywords)
- Artificial pancreas (AC)
- decision support
- diabetes
- glucose metabolism
- patient variability
- physiology-based pharmacokinetics and pharamcodynamics (PBPK/PD)
- predictive control
- predictive models